Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].


Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
May 2021
Historique:
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 8 6 2021
Statut: epublish

Résumé

[This corrects the article DOI: 10.1016/j.gore.2020.100648.].

Identifiants

pubmed: 34095420
doi: 10.1016/j.gore.2021.100740
pii: S2352-5789(21)00045-X
pmc: PMC8169695
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

100740

Commentaires et corrections

Type : ErratumFor

Informations de copyright

© 2021 The Author(s).

Auteurs

Jonathan Oh (J)

Texas Oncology, P.A., Dallas, TX, United States.

Minal Barve (M)

Texas Oncology, P.A., Dallas, TX, United States.
Mary Crowley Cancer Research Centers, Dallas, TX, United States.

Neil Senzer (N)

Gradalis, Inc., Carrolton, TX, United States.

Phylicia Aaron (P)

Gradalis, Inc., Carrolton, TX, United States.

Luisa Manning (L)

Gradalis, Inc., Carrolton, TX, United States.

Gladice Wallraven (G)

Gradalis, Inc., Carrolton, TX, United States.

Ernest Bognar (E)

Gradalis, Inc., Carrolton, TX, United States.

Laura Stanbery (L)

Gradalis, Inc., Carrolton, TX, United States.

Staci Horvath (S)

Gradalis, Inc., Carrolton, TX, United States.

Meghan Manley (M)

Gradalis, Inc., Carrolton, TX, United States.

John Nemunaitis (J)

Gradalis, Inc., Carrolton, TX, United States.

Adam Walter (A)

ProMedica, Toledo, OH, United States.

Rodney P Rocconi (RP)

University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States.

Classifications MeSH